AMASSE CAPITAL (08168): Deng Yaoji and Song Kunxiang have been appointed as independent non-executive directors.
Baoji Capital (08168) announced that Ms. Huang Zhien has submitted her resignation as an independent non-executive director due to personal matters and health issues, effective from August 19, 2026.
AMASSE CAPITAL (08168) announced that Ms. Huang Zhien has submitted her resignation as an independent non-executive director due to other personal matters and health issues, effective from August 19, 2026.
Mr. Deng Yaoki and Mr. Song Kunxiang have been appointed as independent non-executive directors, effective from August 19, 2026.
From August 19, 2026, (1) Ms. Huang will no longer serve as the Chairman of the Board Audit Committee and a member of the Remuneration Committee and the Board Nomination Committee. (2) Mr. Deng has been appointed as the Chairman of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee. (3) Mr. Song has been appointed as the Chairman of the Remuneration Committee and the Nomination Committee and a member of the Audit Committee.
Related Articles

CMOC Group Limited (03993) announced its interim results, with a net profit attributable to shareholders of approximately 16.152 billion yuan, representing a year-on-year increase of 86.27%. A dividend of 0.95 yuan is proposed for every 10 shares.

Growth momentum continues: "Africa's first consumer goods manufacturing stock" SOFTCARE (02698) accelerates market expansion in the mid-term, with profits increasing by 46% and a dividend payout ratio of 66%.

Jiangsu Hengrui Pharmaceuticals (01276): Tian Fei has been appointed as the Secretary of the Board.
CMOC Group Limited (03993) announced its interim results, with a net profit attributable to shareholders of approximately 16.152 billion yuan, representing a year-on-year increase of 86.27%. A dividend of 0.95 yuan is proposed for every 10 shares.

Growth momentum continues: "Africa's first consumer goods manufacturing stock" SOFTCARE (02698) accelerates market expansion in the mid-term, with profits increasing by 46% and a dividend payout ratio of 66%.

Jiangsu Hengrui Pharmaceuticals (01276): Tian Fei has been appointed as the Secretary of the Board.

RECOMMEND





